A brilliant scientist, Oppenheimer was tasked with the development of the atomic bomb in the top-secret Manhattan Project at Los Alamos, New Mexico during World War II.

Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

This information was highlighted following a recent meeting between Oppenheimer analysts and Veru's management in San Francisco, which increased their confidence in the trial's success.

Oppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (PLRX) to Perform from Outperform without a price target after the company ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering ...

Annovis Bio's CEO to present at Oppenheimer's conference, discussing Phase 3 trial progress and NDA initiatives for buntanetap. Annovis Bio Inc. has announced that its CEO, Dr. Maria Maccecchini ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

This information was highlighted following a recent meeting between Oppenheimer analysts and Veru's management in San Francisco, which increased their confidence in the trial's success. The QUALITY ...